Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last quarter, IMPEDIMED LTD Aktie had revenue of €4.3m and net profit of -€7.65m
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 4.3m | - |
| Gross profit | -3.25m | - |
| Net profit | -7.65m | - |
| EBITDA | -4.55m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €11.14m |
Number of shares | 3.67bn |
52-week high/low | €0.0249 - €0.00182 |
| Dividends | No |
Beta | 1.02 |
P/E ratio | -0.43 |
PEG ratio | 0.37 |
P/B ratio | 1.10 |
P/S ratio | 1.25 |
Company profile
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
| Name | IMPEDIMED LTD Aktie |
| CEO | Erik Anderson |
| Headquarters | Carlsbad,
ca Australia |
| Website | |
| IPO | 24/10/2007 |
| Employees | 66 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Australian Securities Exchange Ltd | IPD.AX |
Pnk | IPDQF |